Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Accumulated Expenses: 2019-2025

Historic Accumulated Expenses for IDEAYA Biosciences (IDYA) over the last 7 years, with Sep 2025 value amounting to $45.3 million.

  • IDEAYA Biosciences' Accumulated Expenses rose 61.11% to $45.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.3 million, marking a year-over-year increase of 61.11%. This contributed to the annual value of $30.4 million for FY2024, which is 61.83% up from last year.
  • Per IDEAYA Biosciences' latest filing, its Accumulated Expenses stood at $45.3 million for Q3 2025, which was up 19.89% from $37.8 million recorded in Q2 2025.
  • IDEAYA Biosciences' 5-year Accumulated Expenses high stood at $45.3 million for Q3 2025, and its period low was $7.8 million during Q1 2021.
  • Over the past 3 years, IDEAYA Biosciences' median Accumulated Expenses value was $24.2 million (recorded in 2024), while the average stood at $25.7 million.
  • As far as peak fluctuations go, IDEAYA Biosciences' Accumulated Expenses spiked by 89.74% in 2021, and later decreased by 9.49% in 2023.
  • Quarterly analysis of 5 years shows IDEAYA Biosciences' Accumulated Expenses stood at $12.3 million in 2021, then spiked by 37.98% to $17.0 million in 2022, then climbed by 10.34% to $18.8 million in 2023, then soared by 61.83% to $30.4 million in 2024, then surged by 61.11% to $45.3 million in 2025.
  • Its last three reported values are $45.3 million in Q3 2025, $37.8 million for Q2 2025, and $32.9 million during Q1 2025.